Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients

Trial Profile

Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs Tyzivumab (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions
  • Sponsors Tychan
  • Most Recent Events

    • 12 Nov 2018 New trial record
    • 29 Oct 2018 According to a WuXi Biologics media release, the trial is administered by SingHealth Investigational Medicine Unit, led by Associate Professor Jenny Low, Senior Consultant, Department of Infectious Diseases, Singapore General Hospital and Co-Director, Viral Research and Experimental Medicine Centre@SingHealth Duke-NUS (ViREMiCS). Data management and analytical support in the trial is provided by The Singapore Clinical Research Institute.
    • 29 Oct 2018 According to a WuXi Biologics media release, Tychan has received regulatory approval from the Health Sciences Authority of Singapore to conduct this trial. Recruitment is ongoing in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top